GlaxoSmithKline plc (GSK) War on Ebola Countdown, Palatin Technologies (PTN) Bremelanotide Multimillion-Dollar Deal

Las Vegas, NV, September 3, 2014 (Newswire.com) - The National Institutes of Health, a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency—making important discoveries that improve health and save lives. It is the largest source of funding for medical research in the world and is made up of 27 Institutes and Centers, each with a specific research agenda, often focusing on particular diseases or body systems.

Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin soon by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The early-stage trial will begin initial human testing of a vaccine co-developed by NIAID and GlaxoSmithKline plc (GSK) and will evaluate the experimental vaccine’s safety and ability to generate an immune system response in healthy adults.

NIAID Director said that the experimental vaccine performed extremely well in protecting nonhuman primates from Ebola infection

Ebola virus disease, formerly known as Ebola haemorrhagic fever, is a severe, often fatal illness in humans, characterized by the sudden onset of fever, intense weakness, muscle pain, headache and sore throat. This is followed by vomiting, diarrhoea, rash, impaired kidney and liver function, and in some cases, both internal and external bleeding. Laboratory findings include low white blood cell and platelet counts and elevated liver enzymes.

Ebola is introduced into the human population through close contact with the blood, secretions, organs or other bodily fluids of infected animals. Ebola then spreads in the community through human-to-human transmission, with infection resulting from direct contact (through broken skin or mucous membranes) with the blood, secretions, organs or other bodily fluids of infected people, and indirect contact with environments contaminated with such fluids.

According to the World Health Organization, the 2014 Ebola outbreak is now the largest outbreak in history, with current estimates of 2,473 infections and 1350 deaths since it began in late December 2013.

Initial safety and immunogenicity data from the Phase 1 trials of the NIAID/GSK investigational Ebola vaccine are expected in late 2014.

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

**

Following a 1-for-2,000 reverse split of the Company’s issued and outstanding common stock on August 27, 2014, Crown Equity Holdings Inc.‘s common stock will temporarily trade under the symbol “CRWED” for 20 business days, after which, the “D” will be removed and the symbol will revert to “CRWE”.

The company is currently developing its CRWE Network (CRWE-PR), a growing network of website communities which business model is based on selling advertising to businesses targeting both locally and nationally.

The CRWE Network has reached the 1271st community website in the U.S., associated with 2777 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida, Hattiesburg in Mississippi and 10 provinces in Canada.

Crown Equity Holdings' Roxzu, in development stage, is an on-line e-commerce coupon distribution channel and marketplace for merchants to create brand awareness for their business. Roxzu is focusing first on restaurants and dining but has plans to expand the application to include auto repairs, Realtor, bars, movie theaters, retailers, golf courses, auto dealerships and any other variety of businesses existing within a community.

The geo-location based mobile marketing application Roxzu is expected to be integrated in all the CRWE Network.

Crown Equity Holdings has executed a Letter of Intent to acquire American Video Teleconferencing Corp., (AVOT). The proposed acquisition will be a stock transaction in which Crown Equity Holdings will acquire ninety five percent (95%) of American Video Teleconferencing Corp.’s outstanding shares.

Upon the execution of a definitive agreement and subsequent closing of the transaction, it is envisioned that American Video Teleconferencing Corp. will become a subsidiary of Crown Equity Holdings.

Crown Equity Holdings may then merge its subsidiary Roxzu, into American Video Teleconferencing Corp.

The CRWE-PR Finance website allows Crown Equity Holdings the instant distribution of information to the entire CRWE Network.

CRWE Network’s goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums, while providing micro community news, information and business directory content.

**

Female Sexual Dysfunction (FSD) is a multifactorial condition that has anatomical, physiological, medical, psychological and social components.

FSD includes four disorders, hypoactive sexual desire disorder, female sexual arousal disorder, sexual pain disorder and orgasmic disorder. To establish a diagnosis of FSD, these syndromes must be associated with personal distress, as determined by the affected women.

Research suggests that the majority of women experience sexual dysfunction at some point in their lives, and for many it is an ongoing or recurring issue.

FSD impacts on women’s sexual functioning and on their overall sense of wellbeing. It is associated with depression and relationship satisfaction. Although it is not clear whether FSD causes depression and relationship satisfaction or vice versa, it is likely that, at least in some cases, FSD leads to depression and dissatisfaction with relationships.

Approximately 40 million American women are affected by FSD. The National Health and Social Life Survey, a probability sample study of sexual behavior in a demographically representative cohort of United States adults ages 18 to 59, found that approximately 43% of women suffer from some form of FSD.

There are no Food and Drug Administration approved drugs for FSD.

Palatin Technologies Inc. (PTN) reported that it has entered into a collaboration and license agreement with Gedeon Richter Plc. to co-develop and commercialize bremelanotide for female sexual dysfunction (FSD) indications in the European Union, other European countries and additional selected countries.

Under the terms of the agreement, PTN will receive total upfront payments of €7.5 million ($9.9 million). PTN and Richter will each contribute to the European co-development activities (primarily one phase 3 clinical trial in Europe) for obtaining regulatory approval in Europe. PTN anticipates that its part of the European co-development activities will be cash neutral through the European regulatory filing stage. All sales, marketing, and commercial activities and associated costs in the licensed territory will be the sole responsibility of Richter.

PTN will additionally receive €2.5 million ($3.3 million) upon initiation of its phase 3 clinical trial program in the United States. PTN is also eligible to receive €20 million ($26.4 million) regulatory related milestones. PTN has the potential to receive up to €60 million ($79.2 million) potential sales related milestones and low double-digit royalties on net sales in the licensed territory.

PTN is developing bremelanotide subcutaneous for the treatment of FSD in premenopausal women diagnosed with FSD. Bremelanotide, which is a melanocortin agonist (a compound which binds to a cell receptor and triggers a response) drug candidate, is a synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone).

PTN is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.

**

Read Full Disclaimer at www.finance.crwe-pr.com/disclaimer